Entry into the Pharmaceutical Business (Unapproved Drug Introduction Support Business)
First written in FY2025. 5 of 6 entries say "Advanced", first in FY2026-H1. Latest entry: 2026-08-06.
2 other companies' latest entry also says "Advanced".
- 2026-08-06AdvancedEarnings
「Among these initiatives, in the pharmaceutical business, one of the major challenges for the Group, namely the unapproved-drug introduction support business, the Company newly established 株式会社メドリープファーマ, a consolidated subsidiary, on 16 September 2025. Research and development is progressing, including the advancement of its novel drug candidate, maltol ferric iron (development code: ST10), to Phase 2 trials, and the Company continues to make research and development investments.」
Describes the advancement of メドリープファーマ's novel drug candidate to Phase 2 trials and the continued investment in research and development as concrete progress. - FY2026AdvancedAnnual report
「In the pharmaceutical business (support for the introduction of unapproved drugs), one of the Group's major challenges, the company established MedLeap Pharma Co., Ltd. (a consolidated subsidiary) on 16 September 2025 and began developing the business in concrete terms.」
Regarding entry into the pharmaceutical business, the company established MedLeap Pharma and began developing the business in concrete terms. - FY2026-H1AdvancedAnnual report
「Among the Group's major challenges, the pharmaceutical business (support for the introduction of unapproved drugs) established MedLeap Pharma Co., Ltd. (a consolidated subsidiary) on 16 September 2025 and began developing the business in concrete terms.」
Regarding the policy of entering the pharmaceutical business, the company reports progress in establishing MedLeap Pharma on 16 September 2025 and beginning concrete business development. - FY2025First statedAnnual report
「④ Pharmaceutical business (support for the introduction of unapproved drugs) segment: To contribute, even if only to a small extent, to eliminating Japan's drug lag and drug loss, and to support the sustainable growth and enhancement of the Group's corporate value over the medium to long term, the company will enter the business of supporting the introduction of promising pharmaceuticals approved in Europe and the United States but not yet approved in Japan. 1) The Medium-Term Management Plan 2027 will be allocated to the research and development period. The company will invest in research and development expenses as far ahead of schedule as possible, with the aim of obtaining approval at an early stage.」
The Medium-Term Management Plan 2027 sets out, for the first time, the policy of entering the business of supporting the introduction of pharmaceuticals approved in Europe and the United States but not yet approved in Japan, allocating resources to the research and development period, and seeking early approval.